ATOSSA THERAPEUTICS INC. - COMMON STOCK

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

09 апр 2024 10:59:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

05 апр 2024 08:58:53 Источник NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

04 апр 2024 10:38:29 Источник NetDania Notify

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

01 апр 2024 15:00:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

01 апр 2024 11:27:21 Источник NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

28 мар 2024 09:08:00 Источник NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

26 мар 2024 08:45:03 Источник NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

25 мар 2024 09:40:51 Источник NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

20 мар 2024 08:45:01 Источник NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

19 мар 2024 09:49:14 Источник NetDania Notify

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

19 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

18 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

12 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

06 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

22 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

07 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire

Atossa Therapeutics Issues Letter to Shareholders

09 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

04 дек 2023 07:30:00 Источник Nasdaq GlobeNewswire

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

20 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

13 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire